Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Pfizer Beats Q4, FY ’24 profit estimates, Flat Stocks in Early Trading

PFIZER (PFE) reported the results of profits in the fourth and 2024 entire quarter on Tuesday, overcoming Wall Street’s expectations by a little difference and its shares remained flat after the open market.

Pfizer told its revenue $ 63.6 billion for the whole year, an increase of 7 % compared to 2023. The full revenues won the estimates of Wall Street, the consensus amounting to 62.9 billion dollars, and profits for the $ 3.12 shares worth $ 2.97.

For the fourth quarter of 2024, Pfizer recorded $ 17.8 billion, compared to unanimity estimates of $ 17.3 billion, which represents a 21 % increase over the same quarter in 2023.

The company continues to focus on reducing its size as Covid-19 products revenue and the demand fades, as it must accommodate the suspicious Wall Street about its future. Pfizer has announced a plan to achieve $ 4.5 billion savings by the end of 2025 and an additional $ 1.5 billion by 2027 of things such as reducing the volume of manufacturing and cutting some research and development programs.

The company also managed Avoid an active acquisition of his painting Earlier this year, it was given a batch among many other opposite winds that the company continues in the battle until 2025.

Investors are still vigilant as PFIZER continues to create a pipeline and achieve returns on recent acquisitions – which the company needs in order to balance the expected revenue losses from the end of patent in this contract. This includes cancer drugs from SEAGEN acquisition of $ 43 billion, as well as other smaller deals in the past two years.

PFIZER also faces another year of medical care price negotiations this year, after having to negotiate the thinnest blood, made from Bristol Mairescape (BMY), last year. The new menu includes breast cancer drugs and XTandi prostate. With the presence of three drugs controlled by Medicare, as well as a possible negative impact on the position of the new Trump administration on vaccines and advanced approvals, the company faces some pressure from government work.

In this photo illustration, the American PFIZER (NYSE: PFE: PFE) is the multinational displayed on a smartphone with a graphic indicator for the economic stock exchange in the background. (Budrul Chukrut/SOPA Images/Lightrock via Getty Images) · SOPA photos via Getty Images

Other opposite winds of Pfizer are the slowdown in enthusiasm on the oral GLP-1 candidate, Danuglipron. The company was once seen as being able to compete with the market leader (LLY) in the category of birth control pills, but Lilly is now available in its clinical experience. PFIZER experience was officially ended in January, but weight loss data results were not shared.

“I am excited about what awaits us and is sure that we will enhance the value of shareholders because we sharpen our focus to improve the productivity of our research and development pipeline and pay the clear strategic priorities that direct our company in 2025,” said CEO Albert Borla in a statement.

Leave a Reply

Your email address will not be published. Required fields are marked *